| Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, ... New England Journal of Medicine 334 (8), 488-493, 1996 | 1356 | 1996 |
| Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, ... Journal of Clinical Oncology 16 (2), 593-602, 1998 | 827 | 1998 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 674* | 2019 |
| Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients HG Prentice, G Janossy, L Price-Jones, LK Trejdosiewicz, D Panjwani, ... The Lancet 323 (8375), 472-476, 1984 | 434 | 1984 |
| Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia HG Prentice, G Janossy, D Skeggs, HA Blacklock, KF Bradstock, ... The Lancet 319 (8274), 700-703, 1982 | 299 | 1982 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 295 | 2021 |
| Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study M Dimopoulos, DS Siegel, S Lonial, J Qi, R Hajek, T Facon, L Rosinol, ... The lancet oncology 14 (11), 1129-1140, 2013 | 275 | 2013 |
| Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci PD Griffiths, PR Stirk, M Ganczakowski, DD Panjwani, MG Ball, ... The Lancet 324 (8414), 1242-1245, 1984 | 262 | 1984 |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ... The Lancet Haematology 6 (9), e459-e469, 2019 | 234 | 2019 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 214 | 2019 |
| Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation J Patterson, HG Prentice, MK Brenner, M Gilmore, G Janossy, K Ivory, ... British journal of haematology 63 (2), 221-230, 1986 | 203 | 1986 |
| Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. IM Hann, HG Prentice, HA Blacklock, MG Ross, D Brigden, AE Rosling, ... Br Med J (Clin Res Ed) 287 (6389), 384-388, 1983 | 177 | 1983 |
| Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients IM Hann, R Corringham, M Keaney, P Noone, J Fox, M Szawatkowski, ... The Lancet 319 (8276), 826-829, 1982 | 175 | 1982 |
| A technique for rapid isolation of bone marrow mononuclear cells using Ficoll‐Metrizoate and the IBM 2991 blood cell processor M Gilmore, HG Prentice, HA Blacklock, DDF Ma, G Janossy, AV Hoffbrand British Journal of Haematology 50 (4), 619-626, 1982 | 146 | 1982 |
| The effect of total body irradiation and bone marrow transplantation during childhood and adolescence on growth and endocrine function AD Leiper, R Stanhope, T Lau, DB Grant, H Blacklock, JM Chessells, ... British journal of haematology 67 (4), 419-426, 1987 | 138 | 1987 |
| Plasma exchange in Goodpasture’s syndrome IJ Simpson, PB Doak, LC Williams, HA Blacklock, RS Hill, CA Teague, ... American journal of nephrology 2 (6), 301-311, 1982 | 127 | 1982 |
| Use of modified subcutaneous right-atrial catheter for venous access in leukaemic patients HA Blacklock, RS Hill, AG Clarke, MV Pillai, JRD Matthews, JF Wade The Lancet 315 (8176), 993-994, 1980 | 120 | 1980 |
| ABO-incompatible bone-marrow transplantation: removal of red blood cells from donor marrow avoiding recipient antibody depletion HA Blacklock, HG Prentice, JPM Evans, CBT Knight, M Gilmore, ... The Lancet 320 (8307), 1061-1064, 1982 | 86 | 1982 |
| T cell regeneration after allogenic bone marrow transplantation M Favrot, G Janossy, N Tidman, H Blacklock, E Lopez, M Bofill, I Lampert, ... Clinical and experimental immunology 54 (1), 59, 1983 | 85 | 1983 |
| Therapeutic selectivity of and prediction of response to 2'-deoxycoformycin in acute leukaemia HG Prentice, N Lee, H Blacklock, JF Smyth, NH Russell, K Ganeshaguru, ... The Lancet 318 (8258), 1250-1254, 1981 | 79 | 1981 |
